1.Effectiveness of inactivated poliomyelitis vaccine for primary vaccination.
Chang-Gui LI ; Zhi-Fang YING ; Jian-Feng WANG ; Han-Hua FANG ; Yan-Ping LI ; Rong-Cheng LI ; Marie-Claude BONNET ; Yan-Ping ZHANG
Chinese Journal of Preventive Medicine 2009;43(6):501-503
OBJECTIVETo study the immunological effectiveness of inactivated poliomyelitis vaccine (IPV) for children's primary vaccination in China and to compare with the oral poliomyelitis vaccine (OPV) used in routine vaccination.
METHODSThe 2-month-old children were randomly immunized with IPV and OPV, with 208 subjects in each group. The pre- and post-vaccination blood samples were collected. Micro-neutralization method was used to measure the antibody response against 3 types of polioviruses. chi2 test was used to evaluate the statistical difference of protection rates between two groups, while the antibody titers were transformed by logarithm and analyzed by Z-test. P < 0.05 was always used to define the significance of analysis.
RESULTSAfter 3 doses of immunization, the protection rates in IPV group reached to 100.0% (186/186), 97.3% (181/186), 98.9% (184/186) for poliovirus type 1, 2, 3, respectively, and in OPV group were 97.4% (188/193), 100.0% (193/193), 95.3% (184/193), respectively. The geometry mean titers (GMTs) were 151.2, 86.7, 211.3 for IPV group; and 1089.5, 538.2, 203.7 for OPV group. IPV showed comparable protection rates with OPV for type 1 and 2 (chi2(I) = 2.991, P = 0.084; chi2(II) = 3.512, P = 0.061), while type 3 was higher than OPV (chi2(III) = 4.143, P = 0.042). The GMT of type 1 and 2 in IPV group were lower than OPV group (Z(I) = 12.537, P = 0.000; Z(II) = 13.415, P = 0.000), while the GMT of type 3 were comparable in two groups (Z(III) = 0.067, P = 0.947).
CONCLUSIONIPV showed roughly comparable immunological effectiveness in young children. The protection rates for type 1 and 2 were similar to OPV, while type 3 was higher than in OPV group; In terms of GMT,type 1 and 2 in IPV group were lower than OPV, but type 3 were comparable to OPV group.
Antibodies, Viral ; blood ; Humans ; Infant ; Poliomyelitis ; prevention & control ; Poliovirus Vaccine, Inactivated ; immunology ; Poliovirus Vaccine, Oral ; immunology
2.Study of immunogenicity after primary vaccination by different sequential program of inactivated poliovirus vaccine and oral poliovirus vaccine.
Li LU ; Xiao-mei LI ; Dong-lei LIU ; He-run ZHANG ; Zhu-jia-zi ZHANG ; Hai-hong WANG ; Fang LIU ; Zhao-qi NING ; Li-wen ZHANG ; Ping CHU ; Yan-tao XIE ; Ying XU ; Juan LI ; Xing-huo PANG ; Ying DENG
Chinese Journal of Preventive Medicine 2012;46(6):510-513
OBJECTIVETo evaluate immunogenicity after primary vaccination by different sequential program of inactivated poliovirus vaccine (IPV) and oral poliovirus vaccine (OPV).
METHODSChildren of 2 months old (60-89 days) selected in Beijing were assigned to 4 groups, 1 dose IPV plus 2 doses OPV (I-O-O, 122 children), 2 doses IPV plus 1 dose OPV(I-I-O, 103 children), 3 doses IPV (I-I-I, 114 children), and 3 doses OPV (O-O-O, 106 children), and were vaccinated at the age of 2, 3, 4 months. Polio neutralizing antibody titers against poliovirus types 1, 2, and 3 were tested and protective rates were calculated before the 1st dose, after the last dose, and after the 1st and 2nd dose of IPV.
RESULTSAfter the primary immunization, geometric mean titers (GMT) of polio neutralizing antibody titers against poliovirus types 1, 2, and 3 were 788.32, 738.42 and 631.17 in O-O-O group, 212.02, 262.30 and 537.52 in I-I-I group, 940.35, 929.72 and 940.35 in I-O-O group and 901.09, 1102.68 and 1110.12 in I-I-O group (F values were 47.71, 53.84, and 9.81 respectively, all P values<0.01). The protective rate of three types among each group was 98.1% (104/106)-100.0% and the difference was not statistically significant (P>0.05). After the 1(st) dose of IPV, the GMT were 18.88, 37.77, 24.64 and the protective rate was 82.6% (122/138)-96.4% (133/138); after the 2nd dose of IPV, GMT were 177.03, 168.25, 321.86 and the protective rate was 99.1% (108/109)-100.0% (109/109) in antibody types 1, 2 and 3, respectively.
CONCLUSIONGMT of polio neutralizing antibody titers against poliovirus is higher after vaccination by sequential program of IPV and OPV than that by IPV or OPV 3-doses program. High level of protective rate after 2 doses of IPV in I-I-O group may lead to better protection from vaccine associated paralytic poliomyelitis (VAPP). Sequential program of IPV and OPV can be used to maintain high level of herd immunity and to prevent VAPP, and the I-I-O sequential program should be the first choice.
Humans ; Immunization Schedule ; Infant ; Poliovirus Vaccine, Inactivated ; administration & dosage ; immunology ; Poliovirus Vaccine, Oral ; administration & dosage ; immunology ; Vaccines, Attenuated ; immunology
3.An epidemiological study on vaccine derived polio virus circle in Zhenfeng County of Guizhou Province.
Yi-bing TONG ; Da-yong ZHANG ; Jian ZOU ; Li ZHANG ; Hao YU ; Ming LIU
Chinese Journal of Preventive Medicine 2005;39(5):321-323
OBJECTIVETo analyze the event and cause of vaccine derived polio virus (VDPV) circle happened at Yaoshang Village, Wanlan Township, Zhenfeng County, Qianxinan Prefecture, Guizhou Province in August 2004.
METHODSVirus isolation was performed for stool specimens collected from two children cases with acute flaccid paralysis (AFP) reported at Yaoshang Village and 21 normal children under five years old in the same village. And, routine immunization coverage at the Village and AFP incidence and performance of AFP surveillance system in Zhenfeng County were investigated, as well.
RESULTSVaccine derived polio virus 1 (VDPV1) was identified in the feces of two affected children at Yaoshang Village and three other normal children at the same village. Totally, seven cases of AFP have been underreported in Zhenfeng County since 2002. Routine immunization coverage was rather low at Wanlan Township, and nearly nil at Yaoshang Village.
CONCLUSIONSOral polio vaccine (OPV) with attenuated live virus has been used in China for many years to prevent polio. Circulation of VDPV in Zhenfeng County issues a new challenge to eradication of polio. It is necessary to strengthen routine immunization and AFP surveillance to prevent occurrence of VDPV event.
Child, Preschool ; China ; epidemiology ; Feces ; virology ; Humans ; Incidence ; Infant ; Male ; Poliomyelitis ; epidemiology ; transmission ; virology ; Poliovirus ; immunology ; isolation & purification ; Poliovirus Vaccine, Inactivated ; adverse effects ; Poliovirus Vaccine, Oral ; adverse effects
4.The effect of sodium cromoglycate on the induction of experimental IgA nephropathy.
Yonsei Medical Journal 1990;31(1):33-48
Mesangial IgA nephropathy was experimentally induced in ddY mice by oral and parenteral administration of the poliomyelitis vaccine (POLIO), and we then tried to investigate if IgA deposition could be prevented by the concurrent use of sodium cromoglycate (SCG), which is known to inhibit the local mucosal immune reaction. Mucosal and systemic immunity could be induced by the administration of POLIO; proteinuria, increased serum IgA levels, mesangial cell proliferation, mesangial matrix widening, mesangial deposits of IgA, and large electron dense deposits in the mesangium were observed. Concurrent administration of SCG and POLIO resulted in a significant decrease in the serum IgA level and mesangial IgA deposits. The later addition or abstinence of SCG after the 70th day did not influence the glomerular mesangial IgA deposition. But the serum IgA level was still decreased by the continuous treatment of SCG even after the 70th day. Thus, mesangial IgA nephropathy simulating IgA nephropathy in humans could be induced in ddY mice using POLIO and its induction could largely be prevented by the concurrent use of SCG. However mesangial IgA deposits already present could not be cleared by the late administration of SCG.
Animal
;
Cromolyn Sodium/*pharmacology
;
Female
;
Fluorescent Antibody Technique
;
Glomerulonephritis, IGA/*immunology/metabolism/pathology
;
Immunoglobulin A/metabolism
;
Mice
;
Microscopy, Electron
;
Poliovirus Vaccine, Inactivated/*immunology
5.Immunogenicity and safety of a booster dose of inactivated polio vaccine.
Xiao-mei LI ; Zhu-jia-zi ZHANG ; Hai-hong WANG ; Fang LIU ; Li-wen ZHANG ; Ping CHU ; Ying XU ; He-run ZHANG ; Juan LI ; Dong-lei LIU ; Li LU
Chinese Journal of Preventive Medicine 2013;47(10):905-909
OBJECTIVETo evaluate the immunogenicity and safety of a boost dose of inactivated polio vaccine (IPV) among children aged 18 months who had been administered with primary doses of IPV.
METHODSForm 2011 to 2012, a total of 97 children were enrolled in the present study who were vaccinated with IPV at 2, 3, 4 months of age and boosted with the same vaccine at 18 months of age. Anti-poliovirus neutralizing antibody titers in serum were measured before and after booster vaccination, geometric mean titers (GMT) and seroprotection rate were calculated. Adverse events occurring within 30 days after booster vaccination were observed, including pain, redness/swelling and induration at the injection site, fever, vomit, abnormal crying, drowsiness, loss of appetite, irritability, and all other physical discomfort and related medications were also recorded. A descriptive analysis was performed for the safety assessment.
RESULTSImmunogenicity was assessed in 84 subjects. The pre-booster seropositivity rates of neutralizing antibody against poliovirus type 1, 2, 3 before booster were all 100% (84/84) and the corresponding GMT (95% CI) was 1: 148.5 (116.49-189.29) , 1: 237.68 (178.39-316.67) and 1: 231.87 (181.27-296.58) , respectively. The seropositivity rates of neutralizing antibody against the three types of poliovirus after booster were all 100% (84/84) and the corresponding GMT (95% CI) was 1: 1612.14 (1470.57-1767.34) , 1: 1854.92 (1715.83-2005.29) and 1: 1625.50 (1452.12-1819.58) , respectively. The pre-booster titer of neutralizing antibody against poliovirus type 1, 2, 3 mainly ranged 1: 128-1: 512, which accounted for 65% (55/84) , 55% (46/84) , 74% (62/84) in each type. After the booster immunization, titers of neutralizing antibody against type 1, 2, 3 were increased as subjects with titer ≥ 1: 1024 accounted for 94% (78/84) , 95% (80/84) , 92% (77/84) , respectively.Safety was evaluated in 96 subjects, of which 16 subjects reported adverse events with the rate of 17%. The observed local events were mainly tenderness 3% (3/96) , redness/swelling and induration were not reported. The systemic adverse events included loss of appetite (8%, 8/96) , irritability (8%, 8/96) , fever (7%, 7/96) , abnormal crying (6%, 6/96) , drowsiness (6%, 6/96) and vomit (1%, 1/96) . All reported adverse events were mild or moderate. All of the local events occurred in the day of vaccination and lasted for 1-2 days, while systemic events almost developed within 2 days after vaccination and last less than 3 days.
CONCLUSIONIPV booster dose has good immunogenicity and safety profile, which provides effective protection against poliovirus.
Antibodies, Neutralizing ; blood ; Antibodies, Viral ; blood ; China ; Female ; Humans ; Immunization, Secondary ; adverse effects ; Infant ; Male ; Poliomyelitis ; prevention & control ; Poliovirus Vaccine, Inactivated ; adverse effects ; immunology ; therapeutic use
6.Primary vaccination of infants against hepatitis B can be completed using a combined hexavalent diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliomyelitis-Haemophilus influenzae type B vaccine.
Fong Seng LIM ; Htay-Htay HAN ; Jeanne-Marie JACQUET ; Hans L BOCK
Annals of the Academy of Medicine, Singapore 2007;36(10):801-806
INTRODUCTIONChildren in Singapore receive vaccination against hepatitis B virus (HBV) at 0, 1 and 5 or 6 months of age, and vaccination against pertussis, diphtheria, tetanus, and polio at 3, 4 and 5 months of age. Parents often choose to vaccinate with the combined acellular-pertussis-inactivated polio-Hib vaccine (DTPa-IPV/Hib). We investigated whether a combined hexavalent vaccine, DTPa-HBV-IPV/Hib, could replace the separate administration of DTPa-IPV/Hib and HBV for the final vaccination at 5 months of age (Trial DTPa-HBV-IPV-075).
MATERIALS AND METHODSIn an open study, 150 children were randomised to complete their vaccination schedule with DTPa-IPV/Hib + HBV or DTPa-HBV-IPV/Hib.
RESULTSOne month after the final vaccination, there was no difference between groups in seroprotection rates or antibody concentrations against HBV. Seroprotection rates against diphtheria, tetanus, Hib and polio, as well as vaccine response rates to pertussis antigens were also similar between groups. Local and general symptoms occurred at a similar rate after the third dose of either vaccine.
CONCLUSIONThe immunogenicity and reactogenicity of the hexavalent vaccine DTPa-HBV-IPV/Hib (Infanrix hexa, GSK) group is comparable to that of separately administered DTPa-IPV/Hib and HBV vaccines. Combined hexavalent vaccine, DTPa-HBV-IPV/Hib, could replace the separate administration of DTPa-IPV/Hib and HBV for vaccination at 5 months of age, thereby reducing the number of injections required.
Diphtheria ; immunology ; Diphtheria-Tetanus-Pertussis Vaccine ; Female ; Haemophilus Vaccines ; Haemophilus influenzae ; immunology ; Hepatitis B ; prevention & control ; Hepatitis B Antibodies ; blood ; Hepatitis B Vaccines ; administration & dosage ; Humans ; Immunization Schedule ; Infant ; Infant, Newborn ; Male ; Poliovirus Vaccine, Inactivated ; Singapore ; Tetanus ; immunology ; Vaccination ; Vaccines, Combined ; administration & dosage ; Vaccines, Inactivated
7.Effect of 2-phenoxyethanol on potency of Sabin inactivated poliomyelitis vaccine and its safety.
Chuan-xiu BIAN ; Shu-de JIANG ; Jian-yong YANG ; Ming-bo SUN ; Ming-xue XIE ; Xin-wen ZHANG ; Guo-yang LIAO ; Wei-dong LI
Chinese Journal of Experimental and Clinical Virology 2007;21(1):44-46
OBJECTIVETo investigate the effect of 2-phenoxyethanol on potency of Sabin inactivated poliomyelitis vaccine (IPV).
METHODSSabin IPV samples containing 5 mg or 7 mg 2-phenoxyethanol each dosage respectively were placed separately at 4 degrees C, 37 degrees C for 2 days and 7 days. D-antigen contents were tested with ELISA method. Then neutralizing antibodies in mice and guinea pigs were detected. The safety experiment was performed according to unusual toxicity test of China requirement for biological product.
RESULTSAfter addition of 2-phenoxyethanol, the I, II, and III D-antigen contents of Sabin IPV did not change. The antibody levels in mice and guinea pigs were not different between experimental group and control group. Animals were safe during observation period.
CONCLUSION2-Phenoxyethanol had no effect on potency and safety of Sabin IPV. It can be used as antiseptic for Sabin IPV.
Animals ; Anti-Infective Agents, Local ; administration & dosage ; pharmacology ; toxicity ; Antigens, Viral ; analysis ; immunology ; Body Weight ; drug effects ; Cercopithecus aethiops ; Drug Stability ; Enzyme-Linked Immunosorbent Assay ; Ethylene Glycols ; administration & dosage ; pharmacology ; toxicity ; Guinea Pigs ; Mice ; Neutralization Tests ; Poliovirus Vaccine, Inactivated ; administration & dosage ; immunology ; toxicity ; Vero Cells